Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: conventional surgery, neoadjuvant therapy, radionuclide imaging, iodine I 131 monoclonal antibody F19; Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Quality of Life
Interventions: Extra Care (EC) Intervention, Usual Care (UC); Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions: Tovorafenib; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more

Conditions: B-Cell Non-Hodgkin Lymphoma
Interventions: Anakinra, X-Ray Imaging, Positron Emission Tomography, Computed Tomography, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture, Biospecimen Collection; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes
Interventions: Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician; Device · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 7 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more

Conditions: Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Fish oil (eicosapentaenoic acid and docosahexanoic acid); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more

Conditions: Advanced Solid Tumor, Pain
Interventions: Meaning-Centered Pain Coping Skills Training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: B-cell Non Hodgkin Lymphoma
Interventions: 1 X 10^6 cells/kg, 2.5 X 10^6 cells/kg, Dose expansion: The maximum tolerated dose of CAR-T cells; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breastfeeding, Patient Simulation
Interventions: Breastfeeding Skills Workshop; Other
Lead sponsor: LiquidGoldConcept; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Ypsilanti, Michigan

Conditions: Urinary Bladder Neoplasms
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Heart Failure, Congestive
Interventions: Intramyocardial injection of bone marrow mononuclear cells, Intramyocardial injection of CD34+ selected bone marrow mononuclear cells, LVAD alone; Biological · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Oak Lawn, Illinois • Louisville, Kentucky • New York, New York + 3 more

Conditions: Induction of Labor Affected Fetus / Newborn, Cervical Ripening, Patient Satisfaction
Interventions: Outpatient Cervical Ripening, Inpatient Cervical Ripening, Foley catheter placement, Pre-Foley Questionnaire, Post-Foley Questionnaire, Fetal Non-Stress Test; Other · Procedure · Behavioral
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Colorectal Cancer
Interventions: Exercise Program, Telephone-based intervention, Counseling intervention, Questionnaire administration, Relaxation Program; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Female only
Enrollment: 2,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2010
U.S. locations: 134
States / cities: Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more

Conditions: Glioma
Interventions: Retreatment Rhenium Liposome; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cystic Fibrosis
Interventions: QAU145, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lymphocytic Leukemia
Interventions: alemtuzumab, everolimus; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis, Paclitaxel, pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine; Drug · Procedure · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma
Interventions: Regorafenib, Placebo; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 5 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 15 more

Conditions: Patellofemoral Pain
Interventions: Standard of Care Rehabilitation (SOC), Strength Training Rehabilitation Incorporating Power Exercises (STRIPE); Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 40 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Storrs, Connecticut • Orlando, Florida • Toledo, Ohio

Conditions: Familial Adenomatous Polyposis
Interventions: Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo; Drug
Lead sponsor: Cancer Prevention Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Respiratory Device Comfort
Interventions: Respiratory monitor patient interface.; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 20 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Covid19
Interventions: Bucillamine, Placebo; Drug
Lead sponsor: Revive Therapeutics, Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 46
States / cities: Cullman, Alabama • Huntsville, Alabama • Phoenix, Arizona + 38 more

Search by objective public record fields.

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Mohs Surgery: Patient Satisfaction & Quality of Life (QOL)

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

Meaning-Centered Pain Coping Skills Training

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Evaluation of Health Professional Learners' Competence in Newborn Positioning and Attachment Following a Standardized Patient-led Lactation Skills Workshop

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder

Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure

Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor

Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

Strength or Power Training for Patellofemoral Pain

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces

Bucillamine in Treatment of Patients With COVID-19